Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Hazard ratios for invasive ductal carcinomas, invasive lobular carcinomas, and ductal carcinomas in situ

From: Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women

  Invasive ductal carcinoma
(1009 cases)
Invasive lobular carcinoma
(130 cases)
Ductal carcinoma in situ
(459 cases)
Calcium channel blockers
Never used Reference Reference Reference
Former user 1.05 (0.59–1.86) 1.68 (0.41–6.85) 0.98 (0.41–2.38)
Current user (<5 years) 0.66 (0.45–0.97) 2.26 (1.12–4.55) 0.78 (0.46–1.35)
 (5–10 years) 1.05 (0.66–1.66) 1.13 (0.28–4.61) 1.28 (0.68–2.41)
 (10+ years) 0.80 (0.45–1.42) 0.69 (0.10–4.99) 0.80 (0.33–1.94)
All antihypertensives
Never used Reference Reference Reference
Former user 1.03 (0.69–1.53) 0.30 (0.04–2.16) 1.15 (0.66–2.01)
Current user (<5 years) 0.90 (0.74–1.08) 0.88 (0.51–1.50) 1.06 (0.82–1.39)
 (5–10 years) 0.97 (0.77–1.22) 1.21 (0.65–2.24) 0.87 (0.60–1.26)
 (10+ years) 0.94 (0.74–1.19) 0.57 (0.24–1.34) 0.88 (0.60–1.28)
  1. Data presented as hazard ratio (95 % confidence interval)
  2. Hazard ratios were calculated using Cox proportional hazards regression with age as the time scale and adjusted for race/ethnicity, categorized body mass index, parity, age at menarche, menopause status, statin use, smoking status, hormone therapy use, and reported hours of physical activity per week